Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles

Chen, Rujing; Ni, Shuting; Chen, Wangyan; Liu, Mei; Jiao, Feng; Hu, Kaili

doi:10.2147/ijn.s313166

Cited by 24 publications

(16 citation statements)

References 37 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3-mer peptide RGD prepared by Pierschbacher and Ruoslahti from fibronectin ( Pierschbacher and Ruoslahti, 1984 ; Garate et al, 2015 ), can recognize several integrins, some glycoproteins composed of α and β subunits ( Demircioglu and Hodivala-Dike, 2016 ; Cheng and Ji, 2019 ) which are overexpressed on the cancer cell membrane and involved in angiogenesis, tumor growth ( Nieberler et al, 2017 ) and metastasis ( Wu et al, 2019 ; Chen et al, 2021 ). Hazeri et al ( Hazeri et al, 2022 ) fabricated a targeting delivery system for doxorubicin (DOX) with mesoporous silica nanoparticles loaded with AS1411 aptamer and peptide RGDK-octa-arginine.…”

Section: Peptides For Anticancer Drug Vectorsmentioning

confidence: 99%

Recent advances in peptide-based therapeutic strategies for breast cancer treatment

Duns

Dessie

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Breast cancer is the leading cause of cancer-related fatalities in female worldwide. Effective therapies with low side effects for breast cancer treatment and prevention are, accordingly, urgently required. Targeting anticancer materials, breast cancer vaccines and anticancer drugs have been studied for many years to decrease side effects, prevent breast cancer and suppress tumors, respectively. There are abundant evidences to demonstrate that peptide-based therapeutic strategies, coupling of good safety and adaptive functionalities are promising for breast cancer therapy. In recent years, peptide-based vectors have been paid attention in targeting breast cancer due to their specific binding to corresponding receptors overexpressed in cell. To overcome the low internalization, cell penetrating peptides (CPPs) could be selected to increase the penetration due to the electrostatic and hydrophobic interactions between CPPs and cell membranes. Peptide-based vaccines are at the forefront of medical development and presently, 13 types of main peptide vaccines for breast cancer are being studied on phase III, phase II, phase I/II and phase I clinical trials. In addition, peptide-based vaccines including delivery vectors and adjuvants have been implemented. Many peptides have recently been used in clinical treatments for breast cancer. These peptides show different anticancer mechanisms and some novel peptides could reverse the resistance of breast cancer to susceptibility. In this review, we will focus on current studies of peptide-based targeting vectors, CPPs, peptide-based vaccines and anticancer peptides for breast cancer therapy and prevention.

show abstract

Section: Peptides For Anticancer Drug Vectorsmentioning

confidence: 99%

Recent advances in peptide-based therapeutic strategies for breast cancer treatment

Duns

Dessie

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Docetaxel (DTX), similar to PTX, belongs to the family of toxoids 160 . DTX has been confirmed to show inhibitory activity on breast cancer, NSCLC, and other tumours 161 . Cyclodextrin can be used to form a complex to increase the solubility and bioavailability of DTX.…”

Section: Cpps and Anti‐cancer Cargoes Deliverymentioning

confidence: 99%

“…160 DTX has been confirmed to show inhibitory activity on breast cancer, NSCLC, and other tumours. 161 Cyclodextrin can be used to form a complex to increase the solubility and bioavailability of DTX. A novel DDS-D-CNP (DTX-cyclodextrin-polylactic acid-glycolic acid (PLGA) NPs)-R7 synthesised by a double emulsification method can remarkably improve the absorption and bioavailability of DTX as well as its cellular uptake, which is verified by its excellent treatment efficacy on breast cancer cells.…”

Section: Paclitaxelmentioning

confidence: 99%

The role of cell‐penetrating peptides in potential anti‐cancer therapy

Zhou

Zou

Cheng

et al. 2022

Clinical & Translational Med

View full text Add to dashboard Cite

Due to the complex physiological structure, microenvironment and multiple physiological barriers, traditional anti‐cancer drugs are severely restricted from reaching the tumour site. Cell‐penetrating peptides (CPPs) are typically made up of 5–30 amino acids, and can be utilised as molecular transporters to facilitate the passage of therapeutic drugs across physiological barriers. Up to now, CPPs have widely been used in many anti‐cancer treatment strategies, serving as an excellent potential choice for oncology treatment. However, their drawbacks, such as the lack of cell specificity, short duration of action, poor stability in vivo, compatibility problems (i.e. immunogenicity), poor therapeutic efficacy and formation of unwanted metabolites, have limited their further application in cancer treatment. The cellular uptake mechanisms of CPPs involve mainly endocytosis and direct penetration, but still remain highly controversial in academia. The CPPs‐based drug delivery strategy could be improved by clever design or chemical modifications to develop the next‐generation CPPs with enhanced cell penetration capability, stability and selectivity. In addition, some recent advances in targeted cell penetration that involve CPPs provide some new ideas to optimise CPPs.

show abstract

“…The low solubility and hydrophobicity of DTX create difficulties in the administration, so Tween 80 and ethanol are usually used with DTX for its solubilization in clinical application. These solubilizers have serious side effects, causing most patients to have severe allergic reactions, such as cumulative fluid retention, hypersensitivity reactions, and nausea [ 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer

2022

View full text Add to dashboard Cite

Cancer is one of the most lethal diseases in the world, and the development and improvement of treatments used in cancer therapies are extremely important for a better quality of life for patients. In view of the current problems in drug administration such as low solubility and adverse effects, the activity of a solid lipid nanoparticle containing docetaxel (SLN-DTX), a drug already used in conventional therapies, was evaluated in a cell line (MDA-MB-231) of one of the most aggressive types of breast cancer with the worst prognosis, triple-negative breast cancer. Viability tests indicated that SLN-DTX has a greater dependence on the treatment dose when compared to the free drug, which indicates a more controlled release of the drug, and both reduced viability by around 50% at a concentration of 1 µg/mL after 72 h. Transmission electron microscopy (TEM) and confocal and light microscopy analyses indicated that after treatment the cells enter a mitotic catastrophe, characteristic of antimitotic drugs that usually make cells progress to death or senescence. Cells treated with both DTX and SLN-DTX showed significant inhibition of mobility, 73.6% and 66.5% when treated with SLN-DTX and DTX, respectively, compared to the 11.4% of the control after 72 h, characteristics that are very relevant in tumor development and progression. SLN-DTX demonstrated its great potential as a nanocarrier by maintaining and improving the drug’s action in the MDA-MB-231 cell line.

show abstract

Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles

Cited by 24 publications

References 37 publications

Recent advances in peptide-based therapeutic strategies for breast cancer treatment

Recent advances in peptide-based therapeutic strategies for breast cancer treatment

The role of cell‐penetrating peptides in potential anti‐cancer therapy

In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer

Contact Info

Product

Resources

About